A Study to Assess Adults with CIDP Transitioning from IVIg to Efgartigimod PH20 SC

argenx

Status and phase

Enrolling

Phase 4

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy

Treatments

Biological: Efgartigimod PH20 SC

Study type

Interventional

Funder types

Industry

Identifiers

NCT06637072

ARGX-113-2406

Details and patient eligibility

About

This study will measure how adults with CIDP receiving IVIg treatment adjust to efgartigimod PH20 SC. The study duration for each participant will be approximately 17 to 19 weeks.

Enrollment

25 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Is at least 18 years of age and the local legal age of consent
Is diagnosed with CIDP (confirmed or possible CIDP) according to the criteria of the European Academy of Neurology/Peripheral Nerve Society
Is being treated with IVIg every 3-6 weeks, on a stable dose and dosing interval (between 0.5-2 g/kg) for at least 3 doses
If receiving oral corticosteroids, this should be at a stable dose of less than 20 mg a day or less than 40 mg every other day, for at least a month.
If receiving nonsteroidal immunosuppressive medication, this should be at a stable dose for at least 3 months

Exclusion criteria

Besides the indication under study, known autoimmune disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of CIDP or puts the participant at undue risk
Types of other polyneuropathy other than CIDP